| 发明名称 |
CERITINIB FORMULATION |
| 摘要 |
The present disclosure relates to a new pharmaceutical composition comprising Ceritinib. Particularly it is directed to the tablet that is prepared by wet granulation, wherein povidone is used as a binder. Further feature of the composition is that the drug and the binder form the inner phase, whereas all other excipients are added in a powder form as an outer phase. This way, the sticking of the composition is prevented and sufficient tablet hardness can be reached. |
| 申请公布号 |
US2017112834(A1) |
申请公布日期 |
2017.04.27 |
| 申请号 |
US201515313367 |
申请日期 |
2015.05.27 |
| 申请人 |
Novartis AG |
发明人 |
Breulles Sebastien;ENSSLIN Simon |
| 分类号 |
A61K31/506;A61K9/20;A61K9/16 |
主分类号 |
A61K31/506 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A pharmaceutical composition comprising at least 150 mg and up to 750 mg Ceritinib and more than 40 and up to 70 weight percent of Ceritinib based on the total weight of the pharmaceutical composition, wherein the composition comprises granules consisting of or substantially consisting of Ceritinib and a binder and the granules are obtainable by wet granulation. |
| 地址 |
Basel CH |
